Sustiva oral solution discontinued
Sustiva oral solution 30mg/ml (efavirenz), used to treat HIV infection, has been discontinued by Bristol Myers Squibb. The “capsule sprinkle” method has been upgraded to the primary dosing method for patients who cannot swallow pills. In addition, as a result of the Sustiva oral solution discontinuation, the paediatric indication for the Sustiva hard capsules and film coated tablets has been extended to include children from three months of age and weighing at least 3.5kg.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20069516
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com